Your session is about to expire
← Back to Search
Vorinostat + Chemotherapy for Advanced Cancer
Study Summary
This trial is studying two different doses of vorinostat in combination with either carboplatin or paclitaxel to see which works better in treating patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is advanced, cannot be surgically removed, and has no better treatment options.I am allergic to medications similar to paclitaxel, vorinostat, or carboplatin.I cannot swallow pills.I am not pregnant or breastfeeding, and if capable of becoming pregnant, I agree to use contraception during the study.I haven't had chemotherapy or radiotherapy in the last 4 weeks and have recovered from any side effects.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.It's been over 4 weeks since my last cancer treatment, or 6 weeks if it included BCNU or mitomycin C.My kidney function is normal or nearly normal.I am not HIV-positive or not on antiretroviral therapy.I don't have untreated or worsening brain metastases and am not on steroids or certain seizure medications.I am fully active or restricted in physically strenuous activity but can do light work.I have used valproic acid before.
- Group 1: Arm VI (mid- and low-dose vorinostat and paclitaxel)
- Group 2: Arm V (low- and mid-dose vorinostat and paclitaxel)
- Group 3: Arm III (low- and high-dose vorinostat and carboplatin)
- Group 4: Arm II (high- and low-dose vorinostat and carboplatin)
- Group 5: Arm IV (low- and high-dose vorinostat and carboplatin)
- Group 6: Arm I (high- and low-dose vorinostat and carboplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals have been accepted into this trial?
"At this point in time, no new patients are being accepted for this trial. It was originally published on February 9th 2011 and last updated June 28th 2022. However, if you search elsewhere there are currently 5 active studies seeking participants with adult solid neoplasms and 1203 pharmacological trials that have open enrolment periods."
Has the Pharmacological Study been greenlit by the FDA?
"Data associated with the safety and efficacy of this pharmacological study is limited, so it was rated a 1 on our team's scale."
What findings have been made in other research studies pertaining to Pharmacological Study?
"Presently, 1203 clinical trials are being conducted to investigate Pharmacological Study and 334 of those studies are in Phase 3. While Shanghai is the epicenter for these tests, a total of 67318 sites globally have been designated as testing grounds for this research."
What are the predominant indications for Pharmacological Study?
"Pharmacological Study is suitable for alleviating the symptoms of malignant peritoneal neoplasm, advanced endometrial cancer, and palliative therapy."
Is this investigation actively seeking participants?
"This trial has closed its recruitment period and is no longer seeking participants. Initially posted on February 9th 2011, the study was last updated June 28th 2022. For those searching for active studies, there are currently five trials recruiting patients with solid neoplasm; in addition, 1203 pharmacological studies are actively looking for volunteers to join their investigations."
Share this study with friends
Copy Link
Messenger